The role of interleukin-1β in type 2 diabetes mellitus: A systematic review and meta-analysis
Type 2 diabetes mellitus (T2DM) is a multifactorial non-communicable disease that is characterized by insulin resistance and chronic sub-clinical inflammation. Among the emerging inflammatory markers observed to be associated with β-cell damage is interleukin 1β (IL1β), a proinflammatory cytokine th...
| Main Authors: | , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Frontiers Media S.A.
2022-07-01
|
| Series: | Frontiers in Endocrinology |
| Subjects: | |
| Online Access: | https://www.frontiersin.org/articles/10.3389/fendo.2022.901616/full |
| _version_ | 1818160815185854464 |
|---|---|
| author | Hend Alfadul Hend Alfadul Shaun Sabico Nasser M. Al-Daghri |
| author_facet | Hend Alfadul Hend Alfadul Shaun Sabico Nasser M. Al-Daghri |
| author_sort | Hend Alfadul |
| collection | DOAJ |
| description | Type 2 diabetes mellitus (T2DM) is a multifactorial non-communicable disease that is characterized by insulin resistance and chronic sub-clinical inflammation. Among the emerging inflammatory markers observed to be associated with β-cell damage is interleukin 1β (IL1β), a proinflammatory cytokine that modulates important metabolic processes including insulin secretion and β-cell apoptosis. The present systematic review and meta-analysis gathers available evidence on the emerging role of IL1β in T2DM. PubMed and Embase were searched for human studies that assessed 1L1β in T2DM individuals from 2016-2021. Thirteen studies (N=2680; T2DM=1182, controls=1498) out of 523 were included in the systematic review and only 3 studies in the meta-analysis. Assays were the most commonly used quantification method and lipopolysaccharides as the most common stimulator for IL1β upregulation. Random and fixed effects meta-analysis showed non-significant mean differences of IL1β concentrations between the T2DM and controls. Given the high heterogeneity and small subset of studies included, caution is advised in the interpretation of results. The present systematic review and meta-analysis highlights the limited evidence available that could implicate 1L1β as a potent biomarker for T2DM. Standardization of 1L1β assays with larger sample sizes are encouraged in future observational and prospective studies. |
| first_indexed | 2024-12-11T16:07:52Z |
| format | Article |
| id | doaj.art-bcafb85035c04befb1e064bc470d9a3a |
| institution | Directory Open Access Journal |
| issn | 1664-2392 |
| language | English |
| last_indexed | 2024-12-11T16:07:52Z |
| publishDate | 2022-07-01 |
| publisher | Frontiers Media S.A. |
| record_format | Article |
| series | Frontiers in Endocrinology |
| spelling | doaj.art-bcafb85035c04befb1e064bc470d9a3a2022-12-22T00:59:08ZengFrontiers Media S.A.Frontiers in Endocrinology1664-23922022-07-011310.3389/fendo.2022.901616901616The role of interleukin-1β in type 2 diabetes mellitus: A systematic review and meta-analysisHend Alfadul0Hend Alfadul1Shaun Sabico2Nasser M. Al-Daghri3Chair for Biomarkers of Chronic Diseases, Biochemistry Department, College of Science, King Saud University, Riyadh, Saudi ArabiaBiochemistry Department, College of Science, King Saud University, Riyadh, Saudi ArabiaChair for Biomarkers of Chronic Diseases, Biochemistry Department, College of Science, King Saud University, Riyadh, Saudi ArabiaChair for Biomarkers of Chronic Diseases, Biochemistry Department, College of Science, King Saud University, Riyadh, Saudi ArabiaType 2 diabetes mellitus (T2DM) is a multifactorial non-communicable disease that is characterized by insulin resistance and chronic sub-clinical inflammation. Among the emerging inflammatory markers observed to be associated with β-cell damage is interleukin 1β (IL1β), a proinflammatory cytokine that modulates important metabolic processes including insulin secretion and β-cell apoptosis. The present systematic review and meta-analysis gathers available evidence on the emerging role of IL1β in T2DM. PubMed and Embase were searched for human studies that assessed 1L1β in T2DM individuals from 2016-2021. Thirteen studies (N=2680; T2DM=1182, controls=1498) out of 523 were included in the systematic review and only 3 studies in the meta-analysis. Assays were the most commonly used quantification method and lipopolysaccharides as the most common stimulator for IL1β upregulation. Random and fixed effects meta-analysis showed non-significant mean differences of IL1β concentrations between the T2DM and controls. Given the high heterogeneity and small subset of studies included, caution is advised in the interpretation of results. The present systematic review and meta-analysis highlights the limited evidence available that could implicate 1L1β as a potent biomarker for T2DM. Standardization of 1L1β assays with larger sample sizes are encouraged in future observational and prospective studies.https://www.frontiersin.org/articles/10.3389/fendo.2022.901616/fulltype 2 diabetes mellitusinterleukin 1βinflammasomeinflammationinflammatory diseasecytokines |
| spellingShingle | Hend Alfadul Hend Alfadul Shaun Sabico Nasser M. Al-Daghri The role of interleukin-1β in type 2 diabetes mellitus: A systematic review and meta-analysis Frontiers in Endocrinology type 2 diabetes mellitus interleukin 1β inflammasome inflammation inflammatory disease cytokines |
| title | The role of interleukin-1β in type 2 diabetes mellitus: A systematic review and meta-analysis |
| title_full | The role of interleukin-1β in type 2 diabetes mellitus: A systematic review and meta-analysis |
| title_fullStr | The role of interleukin-1β in type 2 diabetes mellitus: A systematic review and meta-analysis |
| title_full_unstemmed | The role of interleukin-1β in type 2 diabetes mellitus: A systematic review and meta-analysis |
| title_short | The role of interleukin-1β in type 2 diabetes mellitus: A systematic review and meta-analysis |
| title_sort | role of interleukin 1β in type 2 diabetes mellitus a systematic review and meta analysis |
| topic | type 2 diabetes mellitus interleukin 1β inflammasome inflammation inflammatory disease cytokines |
| url | https://www.frontiersin.org/articles/10.3389/fendo.2022.901616/full |
| work_keys_str_mv | AT hendalfadul theroleofinterleukin1bintype2diabetesmellitusasystematicreviewandmetaanalysis AT hendalfadul theroleofinterleukin1bintype2diabetesmellitusasystematicreviewandmetaanalysis AT shaunsabico theroleofinterleukin1bintype2diabetesmellitusasystematicreviewandmetaanalysis AT nassermaldaghri theroleofinterleukin1bintype2diabetesmellitusasystematicreviewandmetaanalysis AT hendalfadul roleofinterleukin1bintype2diabetesmellitusasystematicreviewandmetaanalysis AT hendalfadul roleofinterleukin1bintype2diabetesmellitusasystematicreviewandmetaanalysis AT shaunsabico roleofinterleukin1bintype2diabetesmellitusasystematicreviewandmetaanalysis AT nassermaldaghri roleofinterleukin1bintype2diabetesmellitusasystematicreviewandmetaanalysis |